Relugolix not checked

Sumitomo Pharma America, Inc. · TAK-385 · MVT-601

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
5 active
8 in total · 4 in the EU
Targets
 

What this is

How it works
Gonadotropin Releasing Hormone Receptor Antagonist FDA class
How it’s given
“A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.”In the company’s words, NCT05862272 on ClinicalTrials.gov
Tested for
Uterine Fibroids, Endometriosis
Main trialPhase 3
“The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.”In the company’s words, NCT05862272 on ClinicalTrials.gov
Other names
ORGOVYX · TAK-385 · MVT-601 · RVT-601 · T-1331285 · MVT-601A · MYFEMBREE

Other drugs for Uterine Fibroids

All 3 drugs for Uterine Fibroids

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jul 2029 A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Phase 3Completed 31 Dec 2024 Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Phase 3Completed 25 Feb 2025 Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Phase 1Completed 28 May 2024 Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Phase 3Authorised not given Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.
Phase 3Authorised not given EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE)
Phase 2Authorised not given Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO)
Phase 2Authorised not given REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermediate-Risk Prostate Cancer: a Special Focus on Quality of Life and Erectile Function Recovery
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Relugolix

Following is part of Solo: you see every change to Relugolix the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in